EFG Asset Management North America Corp. Acquires 30,055 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

EFG Asset Management North America Corp. boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,443 shares of the biopharmaceutical company's stock after acquiring an additional 30,055 shares during the period. Ultragenyx Pharmaceutical accounts for about 0.8% of EFG Asset Management North America Corp.'s investment portfolio, making the stock its 28th largest holding. EFG Asset Management North America Corp. owned about 0.15% of Ultragenyx Pharmaceutical worth $5,863,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at $292,000. Prudential Financial Inc. increased its holdings in Ultragenyx Pharmaceutical by 659.5% during the fourth quarter. Prudential Financial Inc. now owns 272,940 shares of the biopharmaceutical company's stock valued at $11,483,000 after buying an additional 237,003 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after acquiring an additional 89,389 shares during the last quarter. Simplify Asset Management Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $707,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $686,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Remove Ads

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares of the company's stock, valued at $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,370 shares of company stock worth $5,751,499 over the last quarter. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded down $1.07 during trading hours on Friday, hitting $37.82. 323,194 shares of the company's stock were exchanged, compared to its average volume of 791,720. The company's 50-day moving average price is $41.64 and its 200-day moving average price is $46.84. Ultragenyx Pharmaceutical Inc. has a 1-year low of $36.71 and a 1-year high of $60.37. The stock has a market capitalization of $3.50 billion, a price-to-earnings ratio of -5.97 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RARE. HC Wainwright restated a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, December 20th. Wedbush restated a "neutral" rating and set a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday. Finally, Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.